<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0005">
 <label>Table 1</label>
 <caption>
  <p>Comparison of SARS and COVID-19.</p>
 </caption>
 <alt-text id="at0060">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Items</th>
    <th align="left">SARS</th>
    <th align="left">COVID-19</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">
     <bold>Pathogen</bold>
    </td>
    <td align="left">SARS-CoV</td>
    <td align="left">SARS-CoV-2</td>
   </tr>
   <tr>
    <td align="left">Primary host</td>
    <td align="left">Bats</td>
    <td align="left">Bats (possible)</td>
   </tr>
   <tr>
    <td align="left">Intermediate host</td>
    <td align="left">Masked civet</td>
    <td align="left">Unknown</td>
   </tr>
   <tr>
    <td align="left">Reproduction number (R
     <sub>0</sub>)
    </td>
    <td align="left">2–5</td>
    <td align="left">2–3</td>
   </tr>
   <tr>
    <td align="left">Time to sequencing completion</td>
    <td align="left">Approximately 3 months</td>
    <td align="left">Approximately 3 weeks</td>
   </tr>
   <tr>
    <td colspan="3" align="left">  </td>
   </tr>
   <tr>
    <td colspan="3" align="left">
     <bold>Epidemiology</bold>
    </td>
   </tr>
   <tr>
    <td align="left">Propagation mode</td>
    <td align="left">Droplets or close contacts</td>
    <td align="left">Droplets or close contacts and high-density aerosols</td>
   </tr>
   <tr>
    <td align="left">Affected countries</td>
    <td align="left">32</td>
    <td align="left">&gt;216</td>
   </tr>
   <tr>
    <td align="left">Number of infected</td>
    <td align="left">8422</td>
    <td align="left">&gt;17,064,064</td>
   </tr>
   <tr>
    <td align="left">Number of deaths</td>
    <td align="left">919</td>
    <td align="left">&gt;668,073</td>
   </tr>
   <tr>
    <td align="left">Geographical distribution</td>
    <td align="left">Mainly in China, Canada, Singapore, and Vietnam</td>
    <td align="left">Global</td>
   </tr>
   <tr>
    <td align="left">Epidemic prevention</td>
    <td align="left">Community lockdown only</td>
    <td align="left">Community, city, even national lockdown</td>
   </tr>
   <tr>
    <td align="left">Vaccine</td>
    <td align="left">No FDA-approved vaccine.</td>
    <td align="left">The first group of volunteers has completed a phase I clinical trial to inject the vaccine.</td>
   </tr>
   <tr>
    <td colspan="3" align="left">  </td>
   </tr>
   <tr>
    <td colspan="3" align="left">
     <bold>Clinical characteristics</bold>
    </td>
   </tr>
   <tr>
    <td align="left">Latency</td>
    <td align="left">3−5 days on average</td>
    <td align="left">3−7 days on average</td>
   </tr>
   <tr>
    <td align="left">Susceptible population</td>
    <td align="left">Young adults</td>
    <td align="left">All people, especially older individuals and people with underlying diseases</td>
   </tr>
   <tr>
    <td align="left">Clinical type</td>
    <td align="left">Mild and severe</td>
    <td align="left">Mild, moderate, severe, critical and convalescent</td>
   </tr>
   <tr>
    <td align="left">Symptoms</td>
    <td align="left">Fever, cough, myalgia, dyspnea, and diarrhea</td>
    <td align="left">Main: Fever, dry cough, fatigue
     <break/>Rare: Upper respiratory symptoms, gastrointestinal symptoms
    </td>
   </tr>
   <tr>
    <td align="left">Pediatric infections</td>
    <td align="left">Similar to adults</td>
    <td align="left">Milder than adults, with some asymptomatic cases</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Laboratory findings</bold>
    </td>
    <td align="left">Leukopenia, lymphopenia, thrombocytopenia, mild abnormal liver function, elevated CRP. Some patients show electrolyte disorder with hyponatremia/hypokalemia or coagulopathy and prolonged clotting time (APTT). D-dimer levels can be increased.</td>
    <td align="left">The total white blood cell count in peripheral blood is normal or decreased, and the lymphocyte count is decreased. CRP and blood sedimentation are increased. In most patients, the liver enzymes, myoglobin, LDH, and D-dimer levels are increased.</td>
   </tr>
   <tr>
    <td colspan="3" align="left">  </td>
   </tr>
   <tr>
    <td colspan="3" align="left">
     <bold>Pathological findings</bold>
    </td>
   </tr>
   <tr>
    <td align="left">Main targets of viral attack</td>
    <td align="left">Lungs, immunological organs, and systemic small vessels</td>
    <td align="left">Lungs</td>
   </tr>
   <tr>
    <td align="left">Pathological findings of lungs</td>
    <td align="left">Fibrosis and consolidation</td>
    <td align="left">Exudative inflammation. Mucus and mucus accumulation in the airway.</td>
   </tr>
   <tr>
    <td colspan="3" align="left">  </td>
   </tr>
   <tr>
    <td colspan="3" align="left">
     <bold>Imaging features</bold>
    </td>
   </tr>
   <tr>
    <td align="left">CT</td>
    <td align="left">Ground-glass opacities with smooth interlobular septal thickening, sometimes with consolidation in a subpleural location.</td>
    <td align="left">Ground-glass opacities (most common), bilateral patchy shadows, local patchy shadows, interstitial abnormalities.</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Diagnostic methods</bold>
    </td>
    <td align="left">RT-PCR, rRT-PCR, RT-LAMP, rRT-LAMP, Coronavirus testing kits</td>
    <td align="left">SARS-CoV-2 nucleic acid testing kits (ﬂuorescent PCR method) and the SARS-CoV-2 nucleic acid sequencing system</td>
   </tr>
   <tr>
    <td colspan="3" align="left">  </td>
   </tr>
   <tr>
    <td colspan="3" align="left">
     <bold>Treatment</bold>
    </td>
   </tr>
   <tr>
    <td align="left">General treatment</td>
    <td align="left">Supportive therapy and antiviral drugs.</td>
    <td align="left">Supportive therapy and antiviral drugs.</td>
   </tr>
   <tr>
    <td align="left">Severe treatment</td>
    <td align="left">Corticosteroid therapy, antiviral agents, anti-infection agents, mechanical ventilation.</td>
    <td align="left">On the basis of symptomatic treatment, preventing complications and secondary infections, treating underlying diseases, and providing respiratory and circulatory support including ventilator and ECMO use.</td>
   </tr>
   <tr>
    <td align="left">TCM treatment</td>
    <td align="left">Used domestically.
     <break/>TCM treatment led to a significant reduction in mortality, a shortened duration of fever, symptom relief, reductions in chest radiograph abnormalities, and reductions in secondary fungal infections among patients receiving glucocorticoids.
    </td>
    <td align="left">Used internationally.
     <break/>TCM treatment plays a significant role in reducing mortality, suppressing progression to severe disease, and curing patients with moderate or mild symptoms.
    </td>
   </tr>
   <tr>
    <td colspan="3" align="left">  </td>
   </tr>
   <tr>
    <td colspan="3" align="left">
     <bold>Prognosis</bold>
    </td>
   </tr>
   <tr>
    <td align="left">Mortality rate</td>
    <td align="left">11%</td>
    <td align="left">Lower than that of SARS</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>SARS: Severe acute respiratory syndrome; COVID-19: Coronavirus disease 2019; CRP: C-reactive protein; APTT: Activated partial thromboplastin time; LDH: Lactate dehydrogenase; RT-PCR: Reverse transcription polymerase chain reaction; RT-LAMP: Reverse transcription Loop-MediatedIsothermal Amplification; PCR: Polymerase chain reaction; ECMO: Extracorporeal Membrane Oxygenation; TCM: Traditional Chinese medicine.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
